Literature DB >> 7540935

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.

R Esnouf1, J Ren, C Ross, Y Jones, D Stammers, D Stuart.   

Abstract

The structure of unliganded HIV-1 reverse transcriptase has been determined at 2.35 A resolution and refined to an R-factor of 0.219 (for all data) with good stereochemistry. The unliganded structure was produced by soaking out a weak binding non-nucleoside inhibitor, HEPT, from pregrown crystals. Comparison with the structures of four different RT and non-nucleoside inhibitor complexes reveals that only minor domain rearrangements occur, but there is a significant repositioning of a three-stranded beta-sheet in the p66 subunit (containing the catalytic aspartic acid residues 110, 185 and 186) with respect to the rest of the polymerase site. This suggests that NNIs inhibit RT by locking the polymerase active site in an inactive conformation, reminiscent of the conformation observed in the inactive p51 subunit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540935     DOI: 10.1038/nsb0495-303

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  113 in total

1.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; H E Aronson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Authors:  J Ren; L E Bird; P P Chamberlain; G B Stewart-Jones; D I Stuart; D K Stammers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-17       Impact factor: 11.205

3.  Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Authors:  Swastika Ganguly; Sankaran Murugesan; Naru Prasanthi; Onur Alptürk; Brian Herman; Nicolas Sluis-Cremer
Journal:  Lett Drug Des Discov       Date:  2010-06-01       Impact factor: 1.150

Review 4.  Allosteric inhibitor development targeting HIV-1 integrase.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  ChemMedChem       Date:  2011-01-12       Impact factor: 3.466

5.  Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor.

Authors:  A A Pilon; J J Lum; J Sanchez-Dardon; B N Phenix; R Douglas; A D Badley
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 6.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

7.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

8.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

9.  Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.

Authors:  Xiaowei Wang; Jianfang Zhang; Yang Huang; Ruiping Wang; Liang Zhang; Kang Qiao; Li Li; Chang Liu; Yabo Ouyang; Weisi Xu; Zhili Zhang; Liangren Zhang; Yiming Shao; Shibo Jiang; Liying Ma; Junyi Liu
Journal:  J Med Chem       Date:  2012-02-17       Impact factor: 7.446

10.  Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors:  H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.